首页|线粒体ClpP激动剂抗肿瘤的研究进展

线粒体ClpP激动剂抗肿瘤的研究进展

扫码查看
线粒体是执行和协调细胞内多种代谢和生命活动的重要细胞器。线粒体功能障碍严重影响细胞的健康,导致神经退行性疾病、心血管疾病以及肿瘤等的发生。线粒体内受损的蛋白或者错误折叠的蛋白堆积会引发整合应激反应和未折叠蛋白反应,线粒体通过蛋白酶体清除异常蛋白从而维持线粒体蛋白质平衡。其中,线粒体丝氨酸蛋白酶ClpP通过与其天然分子伴侣C1pX结合,降解异常蛋白来维持线粒体的正常功能。研究表明,在肿瘤细胞中ClpP高表达,干扰ClpP的蛋白水平导致肿瘤细胞的死亡,且ClpP对肿瘤细胞的生长增殖、侵袭和迁移性能都十分重要,因此ClpP可作为肿瘤病人潜在的药物治疗靶点。近年来,通过靶向激活ClpP的小分子在多种小鼠异种移植肿瘤模型中治疗效果显著,其中以ONC201为代表的Imipridone类化合物因其优异的抗肿瘤作用和安全性已被批准用于临床Ⅲ期试验。在这篇综述中,作者全面概述了ClpP的结构、生理学功能和已报道的小分子激动剂发挥抗肿瘤效应的不同作用机制的相关研究。最后,作者讨论了新型选择性靶向ClpP治疗的小分子化合物的机遇与挑战。
Research Progress of Mitochondrial ClpP Agonists against Tumor
Mitochondria are organelles important for performing and coordinating a wide range of metabolic and vital activities within the cell.Mitochondrial dysfunction severely affects the cell fitness,leading to a series of illness such as neurodegenerative diseases,cardiovascular diseases,and tumorigenesis.The accumulation of damaged or misfolded proteins in mitochondria will trigger integra-tion stress responses and unfolded protein responses.Mitochondrial can coordinate protein homeostasis under the quality control sys-tem formed by a bunch of protease within mitochondrial matrix which can recognize and hydrolyze abnormal proteins to maintain the health of proteome in mitochondrial.In particular,the mitochondrial serine protease ClpP maintains normal mitochondrial function by degrading abnormal unfolded or misfolded proteins with the help of its molecular chaperone,ClpX.Numerous studies have shown that ClpP is highly expressed in many different tumor cells.Disturbance of the expression of ClpP in many sorts of tumor cells including solid tumor and AML will lead to the death of tumor cells.It was also found that ClpP is required for tumor cell proliferation,migra-tion and invasion.Therefore,ClpP can be used as a potential drug therapy target for patients.In recent years,the therapeutic effect of small molecules by targeting and activating ClpP has achieved remarkable progress in different tumor type of xenograft mouse models.Among them,Imipridone analogues,represented by ONC201 with remarkable anti-tumor effects and high safety,have been approved for clinical phase Ⅲ trials.In this review,the authors provide a comprehensive overview of the structure,physiological function,and latest reported studies related to how small molecule agonists of ClpP function as a potent anti-tumor compound and its impact on cell signal pathway.Finally,the authors discuss the opportunities and challenges of new small molecule compounds which can selectively bind and activate homo sapiens ClpP while have little effect on the bacterial ClpP.

ClpP proteaseQuality control of mitochondrionAgonistTumor therapyOXPHOSUPRmt

丁豪、刘笑妍、肖易倍

展开 >

中国药科大学药学院,江苏南京 211198

ClpP蛋白酶 线粒体质控 激动剂 肿瘤治疗 氧化磷酸化 未折叠蛋白反应

国家重点研究计划

2018YFA0902000

2024

药物生物技术
中国药科大学,中国医药科技出版社,中国药学会

药物生物技术

CSTPCD
影响因子:0.463
ISSN:1005-8915
年,卷(期):2024.31(4)